Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | KCNJ1 | P48048 | 4/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.31 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16094263 | 1.00 | CYP11B1 (0.39) | CYP11B1CYP11B2HCAR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL19297940 | 0.84 | HCAR2 (0.47) | CYP11B2HCAR2SMN1; SMN2ALDH1A1ATM | |
| SCHEMBL3415008 | 0.81 | PARP1 (0.38) | HCAR2ATMTSHR | |
| SCHEMBL31659596 | 0.78 | HCAR2 (0.33) | HCAR2ALDH1A1ATM | |
| SCHEMBL25605236 | 0.78 | ATM (0.50) | CYP11B2SMN1; SMN2ALDH1A1ATM | |
| SCHEMBL30989964 | 0.75 | ALOX15 (0.43) | CYP11B1CYP11B2HCAR2ALDH1A1KCNJ1 | |
| SCHEMBL25986847 | 0.75 | CYP1A2 (0.49) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL24921153 | 0.74 | CYP3A4 (0.38) | CYP11B1CYP11B2SMN1; SMN2ALDH1A1 | |
| SCHEMBL30318723 | 0.72 | ICAM1 (0.36) | HCAR2ALDH1A1ATM | |
| SCHEMBL25356220 | 0.72 | CYP1A2 (0.35) | SMN1; SMN2ALDH1A1ATMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122196-A1 | FGFR3 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2025-04-17 | — | — | US | disclosed |
| US-12209086-B2 | FGFR3 inhibitor compounds | ELI LILLY AND COMPANY (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240190870-A1 | FGFR3 INHIBITOR COMPOUNDS | LOXO ONCOLOGY, INC. | 2024-06-13 | — | — | US | disclosed |
| US-11878976-B2 | FGFR3 inhibitor compounds | ELI LILLY AND COMPANY (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230095122-A1 | FGFR3 INHIBITOR COMPOUNDS | LOXO ONCOLOGY, INC. | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11878976-B2 | FGFR3 inhibitor compounds | FGFR3, FGFR1, FGFR2 | CYP11B1 1150/4885CYP11B2 2124/4885HCAR2 2584/4885 |
| US-12209086-B2 | FGFR3 inhibitor compounds | FGFR3, FGFR1, FGFR2 | CYP11B1 1150/4885CYP11B2 2124/4885HCAR2 2584/4885 |
| US-20240190870-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | CYP11B1 1150/4885CYP11B2 2124/4885HCAR2 2584/4885 |
| US-20250122196-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | CYP11B1 1150/4885CYP11B2 2124/4885HCAR2 2584/4885 |
| US-20230095122-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | CYP11B1 1150/4885CYP11B2 2124/4885HCAR2 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.